Compare Amgen, Inc. (AMGN) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares MSCI France ETF — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while iShares MSCI France ETF trades at $47.49. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares MSCI France ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | EWQ | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $417.20 | $48.35 |
52-Week Low | $271.18 | $41.68 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
EWQ, the iShares MSCI France ETF, trades at $47.54, down 0.44% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is concentrated in industrials and benefits from positive momentum in European equities, with a dividend scheduled for June 2026. Recent news highlights France's tech investments and ECB rate decisions influencing regional economic sentiment.
The outlook for EWQ is supported by favorable European market trends and institutional interest, though risks include geopolitical tensions affecting energy prices and potential ECB tightening. Investors should weigh the ETF's exposure to French equities against macroeconomic headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
